Fertility benefits company Progyny (NASDAQ:PGNY) will be announcing earnings results this Thursday after market hours. Here’s what to look for.
Progyny beat analysts’ revenue expectations by 5% last quarter, reporting revenues of $324 million, up 16.5% year on year. It was a satisfactory quarter for the company, with a solid beat of analysts’ sales volume estimates but a slight miss of analysts’ full-year EPS guidance estimates.
Is Progyny a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Progyny’s revenue to grow 5.4% year on year to $320.4 million, slowing from the 8.8% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.43 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Progyny has missed Wall Street’s revenue estimates four times over the last two years.
Looking at Progyny’s peers in the health insurance providers segment, some have already reported their Q2 results, giving us a hint as to what we can expect. CVS Health delivered year-on-year revenue growth of 8.4%, beating analysts’ expectations by 5.1%, and Clover Health reported revenues up 34.1%, topping estimates by 1.7%. CVS Health’s stock price was unchanged following the results.
Read our full analysis of CVS Health’s results here and Clover Health’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the health insurance providers stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Progyny is up 8.9% during the same time and is heading into earnings with an average analyst price target of $26.75 (compared to the current share price of $23.35).
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.